Shares of C-MER Medical Holdings Ltd. (HKG:3309) plummeted by over 10% in intraday trading on September 2, 2024, despite the company reporting modest growth in its first-half 2024 financial results.
The Hong Kong-based medical device company posted a 3.4% year-over-year increase in net income to HK$30.8 million for the first half of 2024. However, revenue declined by 2.9% to HK$922.5 million compared to the same period last year.
Despite the slight improvement in profit margin, driven by lower expenses, the market appeared to react negatively to the tepid revenue growth and the overall financial performance, which fell short of expectations.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。